British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic

Research output: Contribution to journalArticle


  • Nicholas A Kennedy
  • Gareth-Rhys Jones
  • Christopher A Lamb
  • Richard Appleby
  • Ian Arnott
  • R Mark Beattie
  • Stuart Bloom
  • Alenka J Brooks
  • Rachel Cooney
  • Robin J Dart
  • Cathryn Edwards
  • Aileen Fraser
  • Daniel R Gaya
  • Kay Greveson
  • Richard Hansen
  • Ailsa Hart
  • A Barney Hawthorne
  • Bu'Hussain Hayee
  • Jimmy K Limdi
  • Charles D Murray
  • Gareth C Parkes
  • Miles Parkes
  • Kamal Patel
  • Richard C Pollok
  • Nick Powell
  • Chris S Probert
  • Tim Raine
  • Shaji Sebastian
  • Christian Selinger
  • Philip J Smith
  • Catherine Stansfield
  • Lisa Younge
  • James O Lindsay
  • Peter M Irving
  • Charlie W Lees

External organisations

  • University of Exeter Medical School , University of Exeter , Exeter , UK
  • Western General Hospital
  • Chelsea and Westminster NHS Hospital Foundation Trust
  • University Hospital Southampton NHS Foundation Trust
  • University College London Hospitals NHS Foundation Trust
  • Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham
  • Senior Lecturer at University College London and Honorary Consultant Nephrologist at the Centre for Nephrology, UCL and Royal Free Hospital, London, UK
  • Torbay and South Devon NHS Foundation Trust
  • Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Bristol
  • (20) Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Avenue, Glasgow, G12 8QQ, UK
  • Bristol Royal Hospital for Children
  • Department of Life Sciences, Imperial College London, London, UK
  • Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff (UK)
  • King's College Hospital NHS Foundation Trust
  • Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
  • Department of Histopathology, The Royal London Hospital, London, UK.
  • Cambridge University Hospitals NHS Foundation Trust
  • St George's University Hospitals NHS Foundation Trust, London, UK.
  • Kingston University and St George's, University of London, London, UK.
  • Imperial College Healthcare NHS Trust
  • University of Liverpool, Liverpool, UK; The Royal Liverpool University Hospital, Liverpool, UK.
  • Hull University Teaching Hospitals NHS Trust
  • Leeds Teaching Hospitals NHS Trust
  • Liverpool University Hospitals NHS Foundation Trusts
  • Salford Royal NHS Foundation Trust, Salford, UK
  • European Crohn's and Colitis Organisation
  • Guy's and St Thomas' NHS Foundation Trust


The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government's advice for shielding, stringent and standard advice regarding social distancing, respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials.

Bibliographic note

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.


Original languageEnglish
Pages (from-to)984-990
Number of pages7
Issue number6
Early online date17 Apr 2020
Publication statusPublished - Jun 2020


  • Antiviral Agents/adverse effects, Betacoronavirus, Coronavirus Infections/complications, Humans, Immunosuppressive Agents/adverse effects, Inflammatory Bowel Diseases/therapy, Pandemics, Pneumonia, Viral/complications, Risk Assessment, United Kingdom, crohn's colitis, ulcerative colitis, crohn's disease

ASJC Scopus subject areas